Literature DB >> 15341957

The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.

Jennifer A Townes1, Adam Golebiowski, Michael P Clark, Matthew J Laufersweiler, Todd A Brugel, Mark Sabat, Roger G Bookland, Steve K Laughlin, John C VanRens, Biswanath De, Lily C Hsieh, Susan C Xu, Michael J Janusz, Richard L Walter.   

Abstract

4-Aryl-5-pyrimidyl-based cytokine synthesis inhibitors of TNF-alpha production, which contain a novel bicyclic pyrazole heterocyclic core, are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-alpha production in a THP-1 cell-based assay and against human p38 alpha MAP kinase in an isolated enzyme assay. The X-ray crystal structure of a bicyclic pyrazole inhibitor co-crystallized with mutated p38 (mp38) is presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341957     DOI: 10.1016/j.bmcl.2004.07.024

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.

Authors:  Angela S Carlson; Huarui Cui; Anand Divakaran; Jorden A Johnson; Ryan M Brunner; William C K Pomerantz; Joseph J Topczewski
Journal:  ACS Med Chem Lett       Date:  2019-08-02       Impact factor: 4.345

2.  Molecular docking and pharmacological/toxicological assessment of a new compound designed from celecoxib and paracetamol by molecular hybridization.

Authors:  Daiany P B da Silva; Iziara F Florentino; Dayane M da Silva; Roberta C Lino; Carina S Cardoso; Lorrane K S Moreira; Géssica A Vasconcelos; Daniela C Vinhal; Anna C D Cardoso; Bianca Villavicencio; Hugo Verli; Boniek G Vaz; Luciano M Lião; Luiz C da Cunha; Ricardo Menegatti; Elson A Costa
Journal:  Inflammopharmacology       Date:  2018-07-23       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.